Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial

Peter A. Calabresi, Ernst Wilhelm Radue, Douglas Goodin, Douglas Jeffery, Kottil W. Rammohan, Anthony T. Reder, Timothy Vollmer, Mark A. Agius, Ludwig Kappos, Tracy Stites, Bingbing Li, Linda Cappiello, Philipp Von Rosenstiel, Fred D. Lublin

Research output: Contribution to journalArticle

377 Citations (Scopus)

Abstract

Background: Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. Methods: We did this placebo-controlled, double-blind phase 3 study predominantly in the USA (101 of 117 centres). Using a computer-generated sequence, we randomly allocated eligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingolimod 0·5 mg, fingolimod 1·25 mg, or placebo orally once daily (1:1:1; stratified by study centre). On Nov 12, 2009, all patients assigned to fingolimod 1·25 mg were switched to the 0·5 mg dose in a blinded manner after a review of data from other phase 3 trials and recommendation from the data and safety monitoring board, but were analysed as being in the 1·25 mg group in the primary outcome analysis. Our primary endpoint was annualised relapse rate at month 24, analysed by intention to treat. Secondary endpoints included percentage brain volume change (PBVC) from baseline and time-to-disability-progression confirmed at 3 months. This trial is registered with ClinicalTrilals.gov, number NCT00355134. Findings: Between June 30, 2006, and March 4, 2009, we enrolled and randomly allocated 1083 patients: 370 to fingolimod 1·25 mg, 358 to fingolimod 0·5 mg, and 355 to placebo. Mean annualised relapse rate was 0·40 (95% CI 0·34-0·48) in patients given placebo and 0·21 (0·17-0·25) in patients given fingolimod 0·5 mg: rate ratio 0·52 (95% CI 0·40-0·66; p<0·0001), corresponding to a reduction of 48% with fingolimod 0·5 mg versus placebo. Mean PBVC was -0·86 (SD 1·22) for fingolimod 0·5 mg versus -1·28 (1·50) for placebo (treatment difference -0·41, 95% CI -0·62 to -0·20; p=0·0002). We recorded no statistically significant between-group difference in confirmed disability progression (hazard rate 0·83 with fingolimod 0·5 mg vs placebo; 95% CI 0·61-1·12; p=0·227). Fingolimod 0·5 mg caused more of the following adverse events versus placebo: lymphopenia (27 [8%] patients vs 0 patients), increased alanine aminotransferase (29 [8%] vs six [2%]), herpes zoster infection (nine [3%] vs three [1%]), hypertension (32 [9%] vs 11 [3%]), first-dose bradycardia (five [1%] vs one [<0·5%]), and first-degree atrioventricular block (17 [5%] vs seven [2%]). 53 (15%) of 358 patients given fingolimod 0·5 mg and 45 (13%) of 355 patients given placebo had serious adverse events over 24 months, which included basal-cell carcinoma (ten [3%] patients vs two [1%] patients), macular oedema (three [1%] vs two [1%]), infections (11 [3%] vs four [1%]), and neoplasms (13 [4%] vs eight [2%]). Interpretation: Our findings expand knowledge of the safety profile of fingolimod and strengthen evidence for its beneficial effects on relapse rates in patients with relapsing-remitting multiple sclerosis. We saw no effect of fingolimod on disability progression. Our findings substantiate the beneficial profile of fingolimod as a disease-modifying agent in the management of patients with relapsing-remitting multiple sclerosis. Funding: Novartis Pharma AG.

Original languageEnglish (US)
Pages (from-to)545-556
Number of pages12
JournalThe Lancet Neurology
Volume13
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Placebos
Safety
Fingolimod Hydrochloride
Recurrence
Clinical Trials Data Monitoring Committees
Lymphopenia
Macular Edema
Atrioventricular Block
Basal Cell Carcinoma
Herpes Zoster
Brain
Bradycardia

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II) : A double-blind, randomised, placebo-controlled, phase 3 trial. / Calabresi, Peter A.; Radue, Ernst Wilhelm; Goodin, Douglas; Jeffery, Douglas; Rammohan, Kottil W.; Reder, Anthony T.; Vollmer, Timothy; Agius, Mark A.; Kappos, Ludwig; Stites, Tracy; Li, Bingbing; Cappiello, Linda; Von Rosenstiel, Philipp; Lublin, Fred D.

In: The Lancet Neurology, Vol. 13, No. 6, 2014, p. 545-556.

Research output: Contribution to journalArticle

Calabresi, PA, Radue, EW, Goodin, D, Jeffery, D, Rammohan, KW, Reder, AT, Vollmer, T, Agius, MA, Kappos, L, Stites, T, Li, B, Cappiello, L, Von Rosenstiel, P & Lublin, FD 2014, 'Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial', The Lancet Neurology, vol. 13, no. 6, pp. 545-556. https://doi.org/10.1016/S1474-4422(14)70049-3
Calabresi, Peter A. ; Radue, Ernst Wilhelm ; Goodin, Douglas ; Jeffery, Douglas ; Rammohan, Kottil W. ; Reder, Anthony T. ; Vollmer, Timothy ; Agius, Mark A. ; Kappos, Ludwig ; Stites, Tracy ; Li, Bingbing ; Cappiello, Linda ; Von Rosenstiel, Philipp ; Lublin, Fred D. / Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II) : A double-blind, randomised, placebo-controlled, phase 3 trial. In: The Lancet Neurology. 2014 ; Vol. 13, No. 6. pp. 545-556.
@article{26d3018a21aa4ca899476719a7cf19f1,
title = "Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial",
abstract = "Background: Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. Methods: We did this placebo-controlled, double-blind phase 3 study predominantly in the USA (101 of 117 centres). Using a computer-generated sequence, we randomly allocated eligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingolimod 0·5 mg, fingolimod 1·25 mg, or placebo orally once daily (1:1:1; stratified by study centre). On Nov 12, 2009, all patients assigned to fingolimod 1·25 mg were switched to the 0·5 mg dose in a blinded manner after a review of data from other phase 3 trials and recommendation from the data and safety monitoring board, but were analysed as being in the 1·25 mg group in the primary outcome analysis. Our primary endpoint was annualised relapse rate at month 24, analysed by intention to treat. Secondary endpoints included percentage brain volume change (PBVC) from baseline and time-to-disability-progression confirmed at 3 months. This trial is registered with ClinicalTrilals.gov, number NCT00355134. Findings: Between June 30, 2006, and March 4, 2009, we enrolled and randomly allocated 1083 patients: 370 to fingolimod 1·25 mg, 358 to fingolimod 0·5 mg, and 355 to placebo. Mean annualised relapse rate was 0·40 (95{\%} CI 0·34-0·48) in patients given placebo and 0·21 (0·17-0·25) in patients given fingolimod 0·5 mg: rate ratio 0·52 (95{\%} CI 0·40-0·66; p<0·0001), corresponding to a reduction of 48{\%} with fingolimod 0·5 mg versus placebo. Mean PBVC was -0·86 (SD 1·22) for fingolimod 0·5 mg versus -1·28 (1·50) for placebo (treatment difference -0·41, 95{\%} CI -0·62 to -0·20; p=0·0002). We recorded no statistically significant between-group difference in confirmed disability progression (hazard rate 0·83 with fingolimod 0·5 mg vs placebo; 95{\%} CI 0·61-1·12; p=0·227). Fingolimod 0·5 mg caused more of the following adverse events versus placebo: lymphopenia (27 [8{\%}] patients vs 0 patients), increased alanine aminotransferase (29 [8{\%}] vs six [2{\%}]), herpes zoster infection (nine [3{\%}] vs three [1{\%}]), hypertension (32 [9{\%}] vs 11 [3{\%}]), first-dose bradycardia (five [1{\%}] vs one [<0·5{\%}]), and first-degree atrioventricular block (17 [5{\%}] vs seven [2{\%}]). 53 (15{\%}) of 358 patients given fingolimod 0·5 mg and 45 (13{\%}) of 355 patients given placebo had serious adverse events over 24 months, which included basal-cell carcinoma (ten [3{\%}] patients vs two [1{\%}] patients), macular oedema (three [1{\%}] vs two [1{\%}]), infections (11 [3{\%}] vs four [1{\%}]), and neoplasms (13 [4{\%}] vs eight [2{\%}]). Interpretation: Our findings expand knowledge of the safety profile of fingolimod and strengthen evidence for its beneficial effects on relapse rates in patients with relapsing-remitting multiple sclerosis. We saw no effect of fingolimod on disability progression. Our findings substantiate the beneficial profile of fingolimod as a disease-modifying agent in the management of patients with relapsing-remitting multiple sclerosis. Funding: Novartis Pharma AG.",
author = "Calabresi, {Peter A.} and Radue, {Ernst Wilhelm} and Douglas Goodin and Douglas Jeffery and Rammohan, {Kottil W.} and Reder, {Anthony T.} and Timothy Vollmer and Agius, {Mark A.} and Ludwig Kappos and Tracy Stites and Bingbing Li and Linda Cappiello and {Von Rosenstiel}, Philipp and Lublin, {Fred D.}",
year = "2014",
doi = "10.1016/S1474-4422(14)70049-3",
language = "English (US)",
volume = "13",
pages = "545--556",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "6",

}

TY - JOUR

T1 - Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II)

T2 - A double-blind, randomised, placebo-controlled, phase 3 trial

AU - Calabresi, Peter A.

AU - Radue, Ernst Wilhelm

AU - Goodin, Douglas

AU - Jeffery, Douglas

AU - Rammohan, Kottil W.

AU - Reder, Anthony T.

AU - Vollmer, Timothy

AU - Agius, Mark A.

AU - Kappos, Ludwig

AU - Stites, Tracy

AU - Li, Bingbing

AU - Cappiello, Linda

AU - Von Rosenstiel, Philipp

AU - Lublin, Fred D.

PY - 2014

Y1 - 2014

N2 - Background: Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. Methods: We did this placebo-controlled, double-blind phase 3 study predominantly in the USA (101 of 117 centres). Using a computer-generated sequence, we randomly allocated eligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingolimod 0·5 mg, fingolimod 1·25 mg, or placebo orally once daily (1:1:1; stratified by study centre). On Nov 12, 2009, all patients assigned to fingolimod 1·25 mg were switched to the 0·5 mg dose in a blinded manner after a review of data from other phase 3 trials and recommendation from the data and safety monitoring board, but were analysed as being in the 1·25 mg group in the primary outcome analysis. Our primary endpoint was annualised relapse rate at month 24, analysed by intention to treat. Secondary endpoints included percentage brain volume change (PBVC) from baseline and time-to-disability-progression confirmed at 3 months. This trial is registered with ClinicalTrilals.gov, number NCT00355134. Findings: Between June 30, 2006, and March 4, 2009, we enrolled and randomly allocated 1083 patients: 370 to fingolimod 1·25 mg, 358 to fingolimod 0·5 mg, and 355 to placebo. Mean annualised relapse rate was 0·40 (95% CI 0·34-0·48) in patients given placebo and 0·21 (0·17-0·25) in patients given fingolimod 0·5 mg: rate ratio 0·52 (95% CI 0·40-0·66; p<0·0001), corresponding to a reduction of 48% with fingolimod 0·5 mg versus placebo. Mean PBVC was -0·86 (SD 1·22) for fingolimod 0·5 mg versus -1·28 (1·50) for placebo (treatment difference -0·41, 95% CI -0·62 to -0·20; p=0·0002). We recorded no statistically significant between-group difference in confirmed disability progression (hazard rate 0·83 with fingolimod 0·5 mg vs placebo; 95% CI 0·61-1·12; p=0·227). Fingolimod 0·5 mg caused more of the following adverse events versus placebo: lymphopenia (27 [8%] patients vs 0 patients), increased alanine aminotransferase (29 [8%] vs six [2%]), herpes zoster infection (nine [3%] vs three [1%]), hypertension (32 [9%] vs 11 [3%]), first-dose bradycardia (five [1%] vs one [<0·5%]), and first-degree atrioventricular block (17 [5%] vs seven [2%]). 53 (15%) of 358 patients given fingolimod 0·5 mg and 45 (13%) of 355 patients given placebo had serious adverse events over 24 months, which included basal-cell carcinoma (ten [3%] patients vs two [1%] patients), macular oedema (three [1%] vs two [1%]), infections (11 [3%] vs four [1%]), and neoplasms (13 [4%] vs eight [2%]). Interpretation: Our findings expand knowledge of the safety profile of fingolimod and strengthen evidence for its beneficial effects on relapse rates in patients with relapsing-remitting multiple sclerosis. We saw no effect of fingolimod on disability progression. Our findings substantiate the beneficial profile of fingolimod as a disease-modifying agent in the management of patients with relapsing-remitting multiple sclerosis. Funding: Novartis Pharma AG.

AB - Background: Fingolimod has shown reductions in clinical and MRI disease activity in patients with relapsing-remitting multiple sclerosis. We further assessed the efficacy and safety of fingolimod in such patients. Methods: We did this placebo-controlled, double-blind phase 3 study predominantly in the USA (101 of 117 centres). Using a computer-generated sequence, we randomly allocated eligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingolimod 0·5 mg, fingolimod 1·25 mg, or placebo orally once daily (1:1:1; stratified by study centre). On Nov 12, 2009, all patients assigned to fingolimod 1·25 mg were switched to the 0·5 mg dose in a blinded manner after a review of data from other phase 3 trials and recommendation from the data and safety monitoring board, but were analysed as being in the 1·25 mg group in the primary outcome analysis. Our primary endpoint was annualised relapse rate at month 24, analysed by intention to treat. Secondary endpoints included percentage brain volume change (PBVC) from baseline and time-to-disability-progression confirmed at 3 months. This trial is registered with ClinicalTrilals.gov, number NCT00355134. Findings: Between June 30, 2006, and March 4, 2009, we enrolled and randomly allocated 1083 patients: 370 to fingolimod 1·25 mg, 358 to fingolimod 0·5 mg, and 355 to placebo. Mean annualised relapse rate was 0·40 (95% CI 0·34-0·48) in patients given placebo and 0·21 (0·17-0·25) in patients given fingolimod 0·5 mg: rate ratio 0·52 (95% CI 0·40-0·66; p<0·0001), corresponding to a reduction of 48% with fingolimod 0·5 mg versus placebo. Mean PBVC was -0·86 (SD 1·22) for fingolimod 0·5 mg versus -1·28 (1·50) for placebo (treatment difference -0·41, 95% CI -0·62 to -0·20; p=0·0002). We recorded no statistically significant between-group difference in confirmed disability progression (hazard rate 0·83 with fingolimod 0·5 mg vs placebo; 95% CI 0·61-1·12; p=0·227). Fingolimod 0·5 mg caused more of the following adverse events versus placebo: lymphopenia (27 [8%] patients vs 0 patients), increased alanine aminotransferase (29 [8%] vs six [2%]), herpes zoster infection (nine [3%] vs three [1%]), hypertension (32 [9%] vs 11 [3%]), first-dose bradycardia (five [1%] vs one [<0·5%]), and first-degree atrioventricular block (17 [5%] vs seven [2%]). 53 (15%) of 358 patients given fingolimod 0·5 mg and 45 (13%) of 355 patients given placebo had serious adverse events over 24 months, which included basal-cell carcinoma (ten [3%] patients vs two [1%] patients), macular oedema (three [1%] vs two [1%]), infections (11 [3%] vs four [1%]), and neoplasms (13 [4%] vs eight [2%]). Interpretation: Our findings expand knowledge of the safety profile of fingolimod and strengthen evidence for its beneficial effects on relapse rates in patients with relapsing-remitting multiple sclerosis. We saw no effect of fingolimod on disability progression. Our findings substantiate the beneficial profile of fingolimod as a disease-modifying agent in the management of patients with relapsing-remitting multiple sclerosis. Funding: Novartis Pharma AG.

UR - http://www.scopus.com/inward/record.url?scp=84901197534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901197534&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(14)70049-3

DO - 10.1016/S1474-4422(14)70049-3

M3 - Article

C2 - 24685276

AN - SCOPUS:84901197534

VL - 13

SP - 545

EP - 556

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 6

ER -